Multidisciplinary Vesicle Program (MVP) Publications

  1. Petrovich-Kopitman E., Welsh J. A., Adutler-Lieber S., Dayan A. & Porat Z. (2025). Quantification and characterization of extracellular vesicles by flow cytometry.  . 2025 Oct 15 , :277-315.
  2. Dayan A., Alter J. & Fleminger G. (2024). Catalytic Decontamination of Carbon Monoxide Using Strong MetalSupport Interactions on TiO2 Microparticles.  Catalysts. 2024 Sept , 14 (9).
  3. Levi L., Hikri E., Popovtzer A., Dayan A., Levi A., Bachar G., Mizrachi A. & Shoffel-Havakuk H. (2023). Effect of Opioid Receptor Activation and Blockage on the Progression and Response to Treatment of Head and Neck Squamous Cell Carcinoma.  Journal of Clinical Medicine. 2023 Feb , 12 (4).
  4. Fleminger G. & Dayan A. (2021). The moonlighting activities of dihydrolipoamide dehydrogenase: Biotechnological and biomedical applications.  Journal of Molecular Recognition. 2021 Nov , 34 (11).
  5. Dayan A., Yeheskel A., Lamed R., Fleminger G. & Ashur-Fabian O. (2021). Dihydrolipoamide dehydrogenase moonlighting activity as a DNA chelating agent.  Proteins: Structure, Function and Bioinformatics. 2021 Jan , 89 (1):21-28.
  6. Shelly S., Liraz Zaltsman S., Ben-Gal O., Dayan A., Ganmore I., Shemesh C., Atrakchi D., Garra S., Ravid O., Rand D., Israelov H., Alon T., Lichtenstein G., Sharabi S., Last D., Gosselet F., Rosen V., Burstein G., Friedlander A., Harel R., Vogel G., Schnaider Beeri M., Mardor Y., Lampl Y., Fleminger G. & Cooper I. (2021). Potential neurotoxicity of titanium implants: Prospective, in-vivo and in-vitro study.  Biomaterials. 2021 Sept , 276 .
  7. Remer E., Badarni M., Hikri E., Dayan A., Levi L., Popovtzer A., Iraqi M., Porgador A., Joshua B. Z., Bachar G., Elkabets M., Scaltriti M. & Mizrachi A. (2020). CDK 4/6 inhibition overcomes acquired and inherent resistance to pi3kα inhibition in preclinical models of head and neck squamous cell carcinoma.  Journal of Clinical Medicine. 2020 Oct , 9 (10):1-12.
  8. Dayan A., Fleminger G. & Ashur-Fabian O. (2019). Targeting the Achilles heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase.  Oncogene. 2019 Jun 20 , 38 (25):5050-5061.
  9. Dayan A., Lamed R., Benayahu D. & Fleminger G. (2019). RGD-modified dihydrolipoamide dehydrogenase as a molecular bridge for enhancing the adhesion of bone forming cells to titanium dioxide implant surfaces.  Journal of Biomedical Materials Research - Part A. 2019 Mar , 107 (3):545-551.
  10. Dayan A., Mor Yosef R., Risphon J., Tuval E. & Fleminger G. (2019). In Situ Detoxification of Venomous Agent X Surrogate Profenofos by Doped Titanium Dioxide Nanoparticles under Illumination at the UV and Visible Ranges.  Journal of Physical Chemistry A. 2019 Nov 7 , 123 (44):9456-9461.
  11. Dayan A., Fleminger G. & Ashur-Fabian O. (2018). RGD-modified dihydrolipoamide dehydrogenase conjugated to titanium dioxide nanoparticles- switchable integrin-targeted photodynamic treatment of melanoma cells.  RSC Advances. 2018, 8 (17):9112-9119.
  12. Dayan A., Babin G., Ganoth A., Kayouf N. S., Nitoker Eliaz N., Mukkala S., Tsfadia Y. & Fleminger G. (2017). The involvement of coordinative interactions in the binding of dihydrolipoamide dehydrogenase to titanium dioxideLocalization of a putative binding site.  Journal of Molecular Recognition. 2017 Aug 1 , 30 (8).